Try a new search

Format these results:

Searched for:

person:lissab01

Total Results:

4


Selection of canthopexy techniques

Carraway, James H; Grant, Michael P; Lissauer, Boaz J; Patipa, Michael
PMID: 19341633
ISSN: 1090-820x
CID: 922442

The treatment of eyelid malposition following septal reset blepharoplasty

Lissauer, Boaz J; Barbarino, Sheila
The authors have developed a systematic approach to treating eyelid malposition secondary to septal reset blepharoplasty. A key treatment factor is appropriate timing of interventions, which includes initiating treatment with nonsurgical interventions. Although patients who are unresponsive to nonsurgical measures may express a strong desire to surgically correct the eyelid malposition early on, surgical interventions before 3 to 6 months after the initial surgery can, in many instances, worsen the result.
PMID: 19338936
ISSN: 1090-820x
CID: 922432

Chronic subperiosteal hematic cyst formation twelve years after orbital fracture repair with alloplastic orbital floor implant [Case Report]

Glavas, Ioannis; Lissauer, Boaz; Hornblass, Albert
An 89-year-old female patient with a history of a left orbital floor fracture repair with synthetic implant 12 years prior, presented with a three-week history of blurry vision, inferior conjunctival chemosis and proptosis of the left eye. CT scan revealed a well-circumscribed subperiosteal lesion with superior elevation of the orbital floor implant. The patient underwent transconjunctival orbital surgery with removal of the implant and drainage of the subperiosteal hemorrhagic cyst. The patient had an uncomplicated postoperative course, with resolution of the proptosis, chemosis, and return of normal vision. This case represents an unusual late complication of orbital fracture repair with associated reduced visual acuity
PMID: 15764117
ISSN: 0167-6830
CID: 56051

Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model

Grostern, Richard J; Bryar, Paul J; Zimbric, Michele L; Darjatmoko, Soesiawati R; Lissauer, Boaz J; Lindstrom, Mary J; Lokken, Janice M; Strugnell, Stephen A; Albert, Daniel M
BACKGROUND: Although calcitriol (1,25-dihydroxycholecalciferol) and vitamin D(2) inhibit retinoblastoma growth in the athymic (nude) mouse xenograft (Y-79 cell line) model of retinoblastoma, they can cause severe toxicity. OBJECTIVE: To examine the toxicity of and dose-dependent response for the inhibition of tumor growth for 1alpha-hydroxyvitamin D(2) (1alpha-OH-D(2)), an analogue with reduced systemic toxicity, in the athymic Y-79 mouse model. METHODS: Mice were randomized into treatment and control groups for 5-week toxicity and dose-response studies. Treatment was via oral gavage 5 times per week. Dose-response studies measured tumor inhibition and drug serum levels. Tumor size and body weight were measured weekly together with various criteria for toxicity. Animals were euthanized at the end of the treatment period. Tumors and kidneys were harvested, and serum was analyzed for calcium and drug levels. RESULTS: Doses of 0.1 to 1.2 microg/d were selected on the basis of toxicity studies for the dose-response trial. Tumor weight and volume in the 0.2-microg and 0.3-microg doses were significantly lower than in controls. Mortality rates and kidney calcification in mice treated with doses of 0.1 to 0.3 microg were lower than those observed in studies of calcitriol and vitamin D(2). CONCLUSION: A vitamin D analogue, 1alpha-OH-D(2), inhibits tumor growth in this xenograft model of retinoblastoma with less toxicity than calcitriol and vitamin D(2)
PMID: 12003610
ISSN: 0003-9950
CID: 42872